Article
Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
European journal of haematology - 1 Jul 2017
Lestang Elsa, Peterlin Pierre, Le Bris Yannick, Dubruille Viviane, Delaunay Jacques, Godon Catherine, Theisen Olivier, Blin Nicolas, Mahe Beatrice, Gastinne Thomas, Garnier Alice, Touzeau Cyrille, Voldoire Maud, Bene Marie C, Le Gouill Steven, Milpied Noel, Mohty Mohamad, Moreau Philippe, Guillaume Thierry, Chevallier Patrice
Abstract excerpt
OBJECTIVE: The role of allogenic stem cell transplantation (ASCT) is still debated in myelofibrosis (MF). METHODS: A retrospective analyzed was performed to compare the outcome of 71 patients with intermediate-2 or high-risk Dynamic International Prognosis Scoring System+ (DIPSS+) primary (PMF) or secondary (SMF) myelofibrosis with an indication of ASCT as they ultimately underwent the procedure (n=34) or not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.